<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints</h2>
    <div class="badge">2025-09-08T12:05:37+00:00</div>
    <ul>
      <li>Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints Regeneron Pharmaceuticals (REGN) said phase 3 trials evaluating its investigational allergen-blockin Upgrade</li>
<li>A Silver or Gold subscription plan is required to access premium news articles.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints\n• Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints Regeneron Pharmaceuticals (REGN) said phase 3 trials evaluating its investigational allergen-blockin Upgrade\n• A Silver or Gold subscription plan is required to access premium news articles." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/regeneron-pharmaceuticals-said-phase-3-120537894.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>